Adenosquamous cell lung cancer stage I is a rare form of lung cancer that combines two different cell types—adenocarcinoma and squamous cell carcinoma—caught at an early stage when the tumor has not spread beyond the lung. Understanding treatment options for this uncommon cancer helps patients and their families navigate medical decisions during a challenging time.

How Treatment Decisions Are Made for Early-Stage Disease

When someone receives a diagnosis of stage I adenosquamous cell lung cancer, doctors focus on removing the cancer completely and preventing it from returning. At this early stage, the cancer remains confined to the lung tissue and has not traveled to lymph nodes or other parts of the body. This early detection opens the door to potentially curative treatments, though the mixed nature of the cancer cells—containing both glandular and squamous elements—means that treatment must address both components effectively.^[1]

The treatment approach depends on several factors that doctors carefully evaluate. These include the exact size of the tumor, its precise location within the lung, the patient’s overall health and ability to tolerate surgery, and whether any other medical conditions might affect treatment choices. Because adenosquamous carcinoma represents less than 1% of all lung cancers and has unique biological characteristics, medical teams must balance standard lung cancer treatments with considerations specific to this rare subtype.^[5]

Stage I disease is further divided into substages—IA1, IA2, IA3, and IB—based on tumor size and how deeply it has grown into lung tissue. A stage IA1 tumor measures no larger than 1 centimeter at its widest point, while stage IB tumors can reach up to 4 centimeters. This detailed staging helps doctors predict outcomes and decide whether surgery alone will be sufficient or if additional treatments should be considered to reduce the risk of cancer returning.^[4][8]

Surgery as the Primary Treatment Approach

For patients with stage I adenosquamous lung cancer who are healthy enough to undergo an operation, surgical removal of the tumor represents the main treatment. Surgery offers the best chance for long-term survival in early-stage disease because it physically removes all visible cancer from the body. The goal is to take out the tumor along with a margin of healthy tissue around it, ensuring no cancer cells are left behind.^[6][7]

Several types of surgical procedures may be used depending on the tumor’s size and location. Lobectomy, which involves removing the entire lobe of the lung containing the tumor, is the most common operation for stage I disease. The lungs are divided into lobes—three on the right side and two on the left—and removing one lobe typically allows patients to breathe adequately with the remaining lung tissue. A segmentectomy removes a smaller portion, just the segment of the lobe where the tumor sits, and may be considered for very small tumors or patients with limited lung function. In rare cases where the tumor involves multiple lobes, a pneumonectomy—removal of an entire lung—might be necessary, though this is uncommon in stage I disease.^[3][7]

Research examining outcomes for patients with early-stage adenosquamous carcinoma has shown that surgery combined with a specific surgical approach yields better results than other treatments. Studies analyzing over 1,200 patients with stage I disease found that those who received surgery had significantly better survival rates than patients treated with chemotherapy alone. Interestingly, the type of surgery mattered—patients who underwent lobectomy showed similar survival to those who had even more extensive surgery, suggesting that removing the entire affected lobe provides adequate treatment without needing to remove more lung tissue.^[6][14]

Recovery from lung surgery typically takes several weeks. Patients may experience pain around the incision site, shortness of breath during physical activity, and fatigue as the body heals. The remaining lung tissue gradually expands to fill more of the chest cavity, and most people find their breathing improves steadily over the first few months after surgery. Physical therapy and breathing exercises often help speed recovery and restore lung function.

Chemotherapy After Surgery: Weighing the Benefits

After successful surgery to remove a stage I tumor, doctors must decide whether additional treatment is needed. Adjuvant chemotherapy—chemotherapy given after surgery—aims to destroy any cancer cells that might have escaped into the bloodstream before the tumor was removed, even if they cannot be detected by scans. This approach tries to prevent the cancer from returning in the lungs or appearing in other organs.

The decision about whether to recommend chemotherapy for stage I disease is not always straightforward. Research has shown mixed results regarding its benefit in the earliest stages. For stage IB disease, where tumors are slightly larger (between 3 and 4 centimeters), some studies suggest that chemotherapy may help certain patients live longer, particularly those with additional risk factors. However, for very small stage IA tumors, the benefit of chemotherapy is less clear, and the side effects of treatment may outweigh potential gains.^[6][14]

When chemotherapy is recommended for adenosquamous carcinoma, doctors typically use platinum-based regimens—combinations of drugs that include either cisplatin or carboplatin paired with another chemotherapy medication. These combinations work by damaging the DNA of cancer cells, preventing them from dividing and growing. Because adenosquamous carcinoma contains both adenocarcinoma and squamous cell components, the chemotherapy must be effective against both cell types. Common combinations include carboplatin with paclitaxel (also called Taxol) or carboplatin with pemetrexed.^[1][11]

The standard duration for adjuvant chemotherapy is typically four cycles, given at three-week intervals, meaning the entire treatment course lasts about three months. Research in patients with more advanced disease has shown that completing at least four cycles of platinum-based chemotherapy can significantly improve survival outcomes. Each cycle involves coming to the clinic for an intravenous infusion of the medications, which usually takes several hours.^[1]

Chemotherapy causes side effects because it affects not only cancer cells but also normal cells that divide rapidly, such as those in the bone marrow, digestive tract, and hair follicles. Common side effects include fatigue, nausea and vomiting, loss of appetite, changes in taste, hair thinning or loss, increased risk of infections due to low white blood cell counts, and neuropathy—tingling or numbness in the hands and feet. Most side effects improve after treatment ends, though some, like neuropathy, may persist or improve slowly over many months.

Radiation Therapy for Patients Unable to Have Surgery

For patients with stage I adenosquamous lung cancer who cannot undergo surgery due to other health problems, radiation therapy offers an alternative treatment approach. Radiation therapy uses high-energy beams, similar to X-rays but much stronger, to kill cancer cells. Modern radiation techniques can precisely target the tumor while minimizing damage to surrounding healthy lung tissue and nearby organs like the heart and esophagus.^[3][7]

The radiation is delivered from a machine outside the body in a series of treatments, typically five days per week over several weeks. Each treatment session lasts only a few minutes, though the setup and positioning take longer. The radiation beams pass through the skin and chest wall to reach the tumor deep inside the lung. Unlike chemotherapy, which travels throughout the entire body, radiation affects only the area being treated.

Side effects from chest radiation develop gradually during treatment and may continue for a few weeks after radiation ends. Common effects include fatigue, skin irritation or redness in the treatment area (similar to sunburn), difficulty swallowing if the esophagus is near the treatment field, and cough or shortness of breath from inflammation of the lung tissue. Most of these effects resolve within a few months, though some lung scarring may remain permanently in the treated area.

Targeted Therapies Based on Tumor Characteristics

Recent advances in cancer treatment have led to the development of targeted therapies—drugs designed to attack cancer cells based on specific genetic changes or mutations they carry. For adenosquamous carcinoma, doctors may test the tumor tissue for certain mutations that could make it vulnerable to these newer medications. Because adenosquamous carcinoma contains adenocarcinoma components, it sometimes carries mutations that are more commonly found in pure adenocarcinomas.^[1][5]

One of the most important mutations to test for is in the epidermal growth factor receptor (EGFR) gene. Studies have found that approximately 30% of adenosquamous carcinomas harbor EGFR mutations. When this mutation is present, drugs called EGFR tyrosine kinase inhibitors (TKIs)—including erlotinib, gefitinib, and osimertinib—can be highly effective. These oral medications block the signals that tell cancer cells to grow and divide, essentially putting the brakes on tumor growth. EGFR-TKIs have been shown to work in advanced adenosquamous carcinoma when EGFR mutations are present, though most research has focused on later-stage disease rather than stage I.^[1][5]

Another important mutation to look for is ALK rearrangement, found in about 5% of adenosquamous carcinomas. When this genetic change is present, a drug called crizotinib may be effective. However, the research on using crizotinib specifically for adenosquamous carcinoma is very limited, and most experience comes from treating other types of lung cancer with ALK rearrangements.^[1][5]

Testing tumor tissue for PD-L1 expression is also becoming standard practice. PD-L1 is a protein that cancer cells sometimes display on their surface to hide from the immune system. Studies have found PD-L1 expression in about 11% of the adenocarcinoma component and 28% of the squamous component in adenosquamous carcinomas. This information helps doctors determine whether immunotherapy might be beneficial.^[5][11]

It is important to note that while targeted therapies and immunotherapies have transformed treatment for advanced lung cancer, their role in treating stage I disease is still being studied. Most patients with stage I adenosquamous carcinoma will be treated with surgery and possibly chemotherapy, with targeted therapies or immunotherapy reserved for situations where the cancer returns or spreads despite initial treatment.

Emerging Research and Future Treatment Directions

Scientists continue to study adenosquamous carcinoma to better understand its unique biology and develop more effective treatments. Because this cancer type is so rare, much of what doctors know comes from small studies or from analyzing large databases that include information from many hospitals. Researchers are particularly interested in understanding why adenosquamous carcinoma behaves more aggressively than pure adenocarcinoma or squamous cell carcinoma.

Immunotherapy represents one of the most promising areas of current research for lung cancer treatment. These drugs work by helping the patient’s own immune system recognize and attack cancer cells. Checkpoint inhibitors—drugs that release the brakes on immune cells—have shown remarkable results in some patients with advanced lung cancer. Drugs such as pembrolizumab, nivolumab, and atezolizumab block proteins called PD-1 or PD-L1 that cancer cells use to evade immune detection.^[1][3][7]

While most research on immunotherapy has focused on advanced disease, clinical trials are now exploring whether giving these drugs after surgery (adjuvant immunotherapy) can prevent early-stage lung cancers from returning. Though specific trials focused solely on stage I adenosquamous carcinoma are rare due to the disease’s rarity, patients with this diagnosis may be eligible for broader lung cancer trials. These studies typically compare standard treatment (surgery with or without chemotherapy) against standard treatment plus immunotherapy to see if adding the immune checkpoint inhibitor improves survival.^[5]

Researchers are also working to understand the molecular and genetic characteristics that make adenosquamous carcinoma unique. Some studies have identified that the p53 gene is mutated in about 25% of these tumors, though currently no drugs specifically target this mutation. Understanding which genes are commonly altered in adenosquamous carcinoma may eventually lead to new targeted therapies designed specifically for this rare cancer type.^[5]

Following Up After Treatment

After completing treatment for stage I adenosquamous lung cancer, patients enter a phase called surveillance, where doctors monitor closely for any signs that the cancer might return. This typically involves regular CT scans of the chest, usually every three to six months for the first few years, then less frequently over time. Blood tests, physical examinations, and discussions about new or changing symptoms are also part of routine follow-up care.

The five-year survival rate for patients with stage I adenosquamous carcinoma who undergo surgery varies depending on the specific substage and whether lymph nodes are involved. Studies have reported five-year survival rates around 65% for early-stage adenosquamous carcinoma after surgery, which is somewhat lower than the survival rates for pure adenocarcinoma or squamous cell carcinoma at the same stage. This reflects the more aggressive nature of adenosquamous tumors, though catching the disease at stage I still offers the best opportunity for long-term survival.^[2][5]

Most Common Treatment Methods

• Surgery
  • Lobectomy—removal of the lung lobe containing the tumor—is the most common surgical procedure for stage I disease
  • Segmentectomy removes a smaller portion of lung tissue and may be used for very small tumors or patients with limited lung function
  • Pneumonectomy, or removal of an entire lung, is rarely needed for stage I cancer
  • Surgery offers the best chance for cure in early-stage disease when patients are healthy enough to undergo the operation
• Chemotherapy
  • Platinum-based combinations, typically carboplatin with paclitaxel (Taxol), are used when chemotherapy is recommended
  • Treatment aims to destroy any remaining cancer cells after surgery to prevent recurrence
  • Standard treatment involves four cycles given at three-week intervals
  • The benefit of chemotherapy for stage IA disease is uncertain, but it may help some patients with stage IB tumors
• Radiation Therapy
  • Used primarily for patients who cannot undergo surgery due to other health conditions
  • High-energy beams precisely target the tumor while sparing surrounding healthy tissue
  • Typically delivered in daily treatments over several weeks
• Targeted Therapy
  • EGFR tyrosine kinase inhibitors (erlotinib, gefitinib, osimertinib) may be effective when EGFR mutations are present, found in about 30% of adenosquamous carcinomas
  • Crizotinib may work for tumors with ALK rearrangements, present in approximately 5% of cases
  • Testing tumor tissue for these genetic changes helps identify which patients might benefit from targeted drugs
• Immunotherapy
  • Checkpoint inhibitors help the immune system recognize and attack cancer cells
  • PD-L1 testing determines which patients are most likely to respond to these drugs
  • Currently being studied in clinical trials for early-stage disease
  • May represent a future treatment option for preventing cancer recurrence after surgery